ASCO 2022 Conference Coverage


 

ASCO 2022 PACIFIC Trial Updates: Response Kinetics, Safety & Efficacy of Brentuximab Vedotin & Nivolumab +/- R-CHP for Untreated PMBL

405 views
June 7, 2022
0 Comments
Login to view comments. Click here to Login
Lymphoma